Shares Of Prima Biomed Surge 266% After Reported Positive Phase 2 Results In Ovarian Cancer
May 20, 2015 at 19:32 PM EDT
Stock soars 266% as PBMD reports an improvement of overall survival against placebo in second Remission Ovarian Cancer Population.
